EORTC introduces new quality of life module to measure cancer-related fatigue

In an article published in the Journal of the National Cancer Institute, EORTC describes a new measurement tool that provides quantitative measurement of cancer-related fatigue in conjunction with the existing EORTC quality of life core questionnaire. The EORTC QLQ-FA12 module assesses physical, cognitive and emotional aspects of cancer-related fatigue and was validated in a study involving 946 patients in 17 centers across 11 countries.

“Fatigue is one of the factors that most greatly affect quality of life in patients,” says Prof Joachim Weis, Principal Investigator for the study. “Because it is suggestive, it has traditionally been hard to measure, and patients often face a lack of understanding from their entourage and treating specialists. Providing a scientifically validated tool to objectively measure cancer-related fatigue will help improve patient-doctor dialogue around cancer management options.”

“While some tools to measure cancer-related fatigue are available, the EORTC tool was validated using state-of-the-art guidelines, measuring applicability and reliability across languages and patient types (curative, palliative, recent survivor and long-term survivor),” said Andrew Bottomley, Assistant Director and Head of EORTC’s Quality of Life department. “It therefore provides a unique standardized questionnaire that allows clinicians to make reliable comparisons over time and between patient subgroups.”

The module, to be used in conjunction with the EORTC QLQ-C30 questionnaire, is available from the EORTC Quality of Life group (link) in Arabic, Dutch, English, French, German, Italian, Mandarin, Norwegian, Polish, Spanish, and Swedish.

Back to news list

Related News

  • EORTC strategic meeting with Middle Eastern Ambassadors

  • EORTC Quality of Life Group projects to be presented at ISOQOL 2023

  • Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study

  • “Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference

  • Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma

  • Joint Statement: health organisations define EHDS’ opt out required for life saving research

  • Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

  • Full validation of the EORTC CAT Core

  • SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials

  • Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types